PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.49%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-15.26%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-50.43%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-43.14%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-43.14%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
5.01%
Share count expansion well above GNPX's 5.88%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.01%
Diluted share count expanding well above GNPX's 6.02%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-30.81%
Negative OCF growth while GNPX is at 43.40%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-30.34%
Negative FCF growth while GNPX is at 41.17%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52488.47%
Negative 10Y OCF/share CAGR while GNPX stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-16557.44%
Negative 5Y OCF/share CAGR while GNPX is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-182.36%
Negative 3Y OCF/share CAGR while GNPX stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-47013.60%
Negative 10Y net income/share CAGR while GNPX is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-7873.57%
Negative 5Y net income/share CAGR while GNPX is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-9.65%
Negative 3Y CAGR while GNPX is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
20722.38%
Equity/share CAGR of 20722.38% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
5960.52%
Equity/share CAGR of 5960.52% while GNPX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
359.30%
Equity/share CAGR of 359.30% while GNPX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Negative asset growth while GNPX invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-9.39%
We have a declining book value while GNPX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-49.71%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.16%
R&D dropping or stable vs. GNPX's 42.75%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
23.98%
SG&A declining or stable vs. GNPX's 651.65%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.